Screener
Amneal Pharmaceuticals, Inc. AMRX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Foreign exchange (loss) gain, net | (1,950) | 8,256 | (9,750) | 12,503 |
| Loss on refinancing | — | — | (3,510) | — |
| Increase in tax receivable agreement liability | (2,439) | (4,420) | (106) | (15,107) |
| Other income, net | 653 | 1,604 | 1,395 | 2,122 |
| Total other expense, net | (58,779) | (59,661) | (120,375) | (122,522) |
| Income before income taxes | 70,990 | 51,711 | 151,166 | 89,197 |
| Provision for income taxes | 1,376 | 16,101 | 3,552 | 28,969 |
| Net income | 69,614 | 35,610 | 147,614 | 60,228 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s other income, net (note 6)?
- Amneal Pharmaceuticals, Inc. (AMRX) reported other income, net (note 6) of $653K in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 59.3% year-over-year, from $1.6M to $653K.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other income, net (note 6)?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s other income, net (note 6) has grown at a 1.9% compound annual growth rate (CAGR), from $15.33M to $16.52M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Amneal Pharmaceuticals, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude